[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liposomal-bupivacaine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liposomal-bupivacaine":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,52,79,106,127,152,183,207,225,240,261,278,302,333,359],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644172","phase-3-liposomal-bupivacaine-plus-plain-bupivacaine-versus-dexamethasone-plus-plain-bupivacaine-in-the-supraclavicular-brachial-plexus-block-in-patients-with-risk-factors-for-severe-acute-postoperative-pain-100644172",false,"NCT07665762","Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain","Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain: a Randomized Controlled Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologist (ASA) status I-III\n* Age 18-90 years old\n* Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)\n* Informed consent obtained\n* Patients identified to be at an elevated risk of suffering from poor postoperative pain control. Patients with one or more of the following risk factors:\n\n  * Severe preoperative pain: defined as worse numerical rating scale (NRS) pain score equal or higher than 6\u002F10 with arm movements at day before surgery.\n  * Preoperative use of opioid: use of strong opioids such as morphine, oxycodone\n  * Depressive symptoms: Patient health questionnaire (PHQ-9) score of 10 or above\n  * Anxiety symptoms: General Anxiety Disorder (GAD-7) score of 10 or above\n  * Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant\n\nExclusion Criteria:\n\n* Revision surgery\n* Previous fractures or surgery in the affected distal radius\n* Surgery involving more than the affected arm\n* Cases with baseline (pre-injury) QuickDASH score worse (higher) than 10 out of 100\n* Respiratory compromise (requires long term oxygen)\n* History of seizures\n* Pre-existing neurological disorder\u002Fdeficit\n* Alcohol or substance abuse\n* Impaired mental state\n* Local infection\n* Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids\n* Impaired renal function (defined as effective glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m2\n* Impaired liver function (defined as plasma bilirubin over 34μmol\u002FL; international normalized ratio \\[INR\\] ≥1.7, alanine aminotransferase \\[ALT\\] over 100U\u002FL, aspartate aminotransferase \\[AST\\] over 100U\u002FL)\n* Coagulopathy (platelet count \\\u003C100,000\u002Fml and\u002For INR ≥ 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB\n* Pregnancy\n* Patient refusal for regional nerve blocks\n* Patient refusal to join the clinical trial\n* Patient unable\u002Funwilling to attend post-op rehabilitation programme","ALL","18 Years","90 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The supraclavicular brachial plexus block (BPB) is a frequently used anaesthetic method for upper limb surgeries, including distal radial fracture surgery. Adding liposomal bupivacaine to BPB has shown promise in enhancing postoperative pain control. A previous randomized controlled trial demonstrated that it reduced pain scores and OBAS compared to plain bupivacaine alone, especially on postoperative day (POD) 1. Adding adjuncts to non-liposomal local anaesthetics can also enhance and prolong postoperative pain relief. The effectiveness of liposomal bupivacaine compared to adjuncts like dexamethasone and dexmedetomidine remains unclear. Since liposomal bupivacaine is more expensive, it is crucial to compare its analgesic efficacy with these alternatives. A randomized controlled trial comparing liposomal bupivacaine versus dexamethasone in the interscalene BPB for shoulder surgery found that liposomal bupivacaine resulted in statistically significantly lower pain scores and less pain interference in the Brief Pain Inventory, although the reduction was not considered clinically relevant. Its high cost may therefore limit its routine use unless specific clinical contexts where its efficacy is maximized are identified. Notably, patients with risk factors like psychological factors, preoperative pain, and prior analgesic use may benefit most from its application.\n\nA randomized controlled trial to compare the analgesic efficacy of liposomal bupivacaine plus plain bupivacaine versus dexamethasone plus plain bupivacaine in supraclavicular BPB for patients at higher risk of poor acute pain control post distal radial fracture surgery will be conducted. Patients with severe preoperative pain, opioid use, depressive symptoms, anxiety symptoms, and\u002For higher energy and high-grade fracture cases will be selected. The primary outcome measured is the intensity of acute postoperative pain with movement in the first 48 hours after surgery. Important secondary outcomes include pain intensity at rest, opioid consumption, OBAS scores, chronic pain, and upper limb functionality.",[27,28,29,30,31,32],"Pain, Postoperative","Liposomal Bupivacaine","Dexamethasone","Supraclavicular Brachial Plexus Block","High Risk Factors","Distal Radial Fracture",[34,35,36,37,38],"supraclavicular brachial plexus block","liposomal bupivacaine","dexamethasone","distal radial fracture","pain","NOT_YET_RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-24","ACTUAL",{"date":45,"type":21},"2026-06-15",{"date":47,"type":21},"2029-03-01",{"name":49,"class":50},"The University of Hong Kong","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100632357","phase-4-effect-of-intercostal-nerve-block-with-liposomal-bupivacaine-on-quality-of-recovery-in-vats-partial-pneumonectomy-100632357","NCT07512635","Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Quality of Recovery in VATS Partial Pneumonectomy","Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Postoperative Quality of Recovery in Patients Undergoing Video-assisted Thoracoscopic Partial Pneumonectomy","Inclusion Criteria:\n\n* Patients scheduled for thoracic surgery under general anesthesia via thoracoscopic approach;\n* Age 18-65 years;\n* Classified as Grade I-II by the American Society of Anesthesiologists (ASA).\n\nExclusion Criteria:\n\n* History of local anesthetic allergy.\n* Chronic opioid users.\n* Contraindications for nerve block, including infection at the puncture site and coagulation disorders;\n* Language communication impairment.\n* Other conditions unsuitable for inclusion in the trial.","65 Years",{"count":61,"type":21},96,[63],"PHASE4","Video-assisted thoracoscopic surgery (VATS) is a minimally invasive approach for partial pneumonectomy, but postoperative pain remains a major challenge affecting recovery. Intercostal nerve block (ICNB) with conventional local anesthetics provides limited duration of analgesia, often insufficient to cover the peak pain period after surgery. Liposomal bupivacaine is a long-acting formulation designed to provide extended analgesia up to 72 hours. This study aims to evaluate the effect of preoperative ICNB with liposomal bupivacaine compared with conventional bupivacaine hydrochloride on postoperative quality of recovery in patients undergoing VATS partial pneumonectomy. The primary outcome is the Quality of Recovery-15 (QoR-15) score at 24 hours postoperatively. We hypothesize that liposomal bupivacaine ICNB results in superior recovery quality compared with conventional bupivacaine, with reduced postoperative pain and opioid consumption.",[66,28],"Pulmonary Nodule",[68,69],"Liposomal bupivacaine","Intercostal nerve block","RECRUITING","2026-06-17",{"date":40,"type":43},{"date":74,"type":43},"2026-04-06",{"date":76,"type":21},"2027-04-30",{"name":78,"class":50},"Sanming First Hospital",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100642566","phase-4-fascia-iliaca-block-using-liposomal-bupivacaine-for-analgesia-after-hip-fracture-surgery-100642566","NCT07643792","Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture Surgery","Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture Surgery: a Randomized Trial","Inclusion Criteria:\n\n* Aged ≥ 55 years.\n* Diagnosed as hip fracture and scheduled to undergo hip replacement surgery.\n* Agree to receive regional nerve block and postoperative patient-controlled intravenous analgesia (PCIA).\n\nExclusion Criteria:\n\n* Inability to communicate due to visual, auditory, language, or other reasons before surgery.\n* Chronic opioid dependence and long-term use of various types of analgesics (for more than 3 months).\n* Severe coagulation abnormalities (International Normalized Ratio \\> 1.7, activated partial thromboplastin time exceeding the normal value by more than 4 seconds, platelet count \\\u003C 80 × 10⁹\u002FL), trauma or infection at the intended puncture site, or severe low back pain.\n* Preoperative severe renal insufficiency (serum creatinine \\> 442 μmol\u002FL or requiring renal replacement therapy), hepatic insufficiency (Child-Pugh class C), or ASA physical status \\> IV.\n* Known allergy to local anesthetics.\n* Any other condition that the investigator or attending physician deems unsuitable for participation in the study.","55 Years",{"count":88,"type":21},148,[63],"Older patients with hip fractures often suffer from severe pain. Inadequate analgesia increases the risk of postoperative delirium, myocardial injury, and other complications. Peripheral nerve block is an important component of multimodal analgesia, but conventional local anesthetics (such as plain bupivacaine) provide only approximately 12 hours of analgesic duration, which is far from covering the most painful 72 hours after surgery. Liposomal bupivacaine has a slow-release property, prolonging the analgesic duration up to 72 hours after a single injection. However, its clinical advantages in hip fracture surgery remain controversial. The investigators suppose that, compared with plain bupivacaine alone, preoperative supra-inguinal fascia iliaca block using liposomal bupivacaine combined with plain bupivacaine can further improve analgesia, decrease opioid consumption, and improve postoperative recovery quality within 72 hours in older patients after hip fracture surgery.",[92,93,94,28,95],"Older Adults","Hip Fracture Surgery","Fascia Iliaca Block","Postoperative Pain",[92,97,94,28,95],"Hip fracture surgery","2026-06-11",{"date":45,"type":43},{"date":101,"type":21},"2026-07",{"date":103,"type":21},"2028-08",{"name":105,"class":50},"Peking University First Hospital",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":51},"100643213","phase-4-the-effect-of-bupivacaine-liposomes-on-postoperative-pain-in-lung-transplant-patients-after-intercostal-nerve-block-a-randomized-controlled-study-100643213","NCT07641647","The Effect of Bupivacaine Liposomes on Postoperative Pain in Lung Transplant Patients After Intercostal Nerve Block: a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with end-stage lung disease undergoing bilateral lung transplantation; Age \\>18 years; Expected discontinuation of mechanical ventilation within 48 hours after surgery; The patient or legally authorized representative signs the informed consent form and agrees to participate in the study and follow-up.\n\nExclusion Criteria:\n\n* Body mass index ≤18 kg\u002Fm² or ≥35 kg\u002Fm²; Allergy or contraindication to local anesthetics; Preoperative tracheal intubation or requirement for extracorporeal life support; Expected use of other types of nerve block; Active systemic infection or infection at the planned block site; Severe hepatic insufficiency; Severe renal impairment; Chronic pain, neuropathic pain, long-term use of analgesics, or use of other psychotropic medications; Preoperative cognitive impairment, cerebrovascular disease, or history of psychiatric disorders; Severe coagulation dysfunction; Concomitant surgery during the same operative session; Pregnant or breastfeeding women.",{"count":113,"type":21},88,[63],"The goal of this clinical trial is to evaluate the efficacy and safety of liposomal bupivacaine for postoperative analgesia in adult patients undergoing lung transplantation. The main questions it aims to answer are:\n\nDoes liposomal bupivacaine reduce postoperative opioid consumption after lung transplantation? Does liposomal bupivacaine relieve postoperative pain without increasing adverse events?\n\nResearchers will compare patients receiving liposomal bupivacaine combined with bupivacaine hydrochloride with patients receiving bupivacaine hydrochloride alone to see whether liposomal bupivacaine provides better postoperative analgesia and reduces opioid requirements after lung transplantation.\n\nParticipants will:\n\nReceive lung transplantation under standard perioperative care. Receive intercostal nerve block with either liposomal bupivacaine combined with bupivacaine hydrochloride or bupivacaine hydrochloride alone.\n\nBe assessed for postoperative opioid consumption, pain scores, recovery-related outcomes, and adverse events after surgery.",[117,118,28],"Lung Transplantation","Pain Management","2026-06-07",{"date":98,"type":43},{"date":122,"type":21},"2026-07-01",{"date":124,"type":21},"2028-07-01",{"name":126,"class":50},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":51},"100638657","efficacy-of-liposomal-bupivacaine-for-transversus-abdominis-plane-block-100638657","NCT07577934","Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block","Liposomal Bupivacaine Versus Ropivacaine for Transversus Abdominis Plane Block in Laparoscopic Cholecystectomy: A Randomized, Single-Blind, Parallel-Group Trial","Inclusion Criteria:\n\n* Age 18-65 years, either gender.\n* Patients scheduled for elective laparoscopic cholecystectomy.\n* ASA physical status I-III.\n* Able to provide written informed consent and complete the 3-month follow-up.\n\nExclusion Criteria:\n\n* History of allergy to local anesthetics.\n* History of dementia, psychosis, or other central nervous system diseases.\n* History of chronic pain or long-term use of opioids or other analgesics.\n* Contraindications to nerve block: infection at puncture site, severe coagulopathy.\n* Severe hepatic or renal dysfunction, pregnancy, or lactation.",{"count":135,"type":21},86,[137],"NA","This is a single-center, randomized, single-blind, parallel-group clinical trial. The study aims to compare the analgesic efficacy of liposomal bupivacaine versus ropivacaine for transversus abdominis plane (TAP) block in patients undergoing laparoscopic cholecystectomy. Eligible participants will be randomly assigned to receive either liposomal bupivacaine or ropivacaine for TAP block during surgery. The primary outcome is the dynamic NRS pain score at 24 hours after surgery. Secondary outcomes include static and dynamic NRS pain scores at multiple time points, QoR-15 recovery quality, time to first rescue analgesia, analgesic consumption, gastrointestinal function recovery, length of hospital stay, and adverse events. Participants will be followed up to 3 months after surgery to evaluate the incidence of chronic post-surgical pain (CPSP). All participants will receive routine clinical care, and participation is voluntary.",[95,28],[28,95,141,142],"Transverse Abdominal Plane Block","Anesthetic Recovery","2026-05-11",{"date":145,"type":43},"2026-05-14",{"date":147,"type":43},"2026-05-10",{"date":149,"type":21},"2026-08-01",{"name":151,"class":50},"Tianjin First Central Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":51},"100632144","liposomal-bupivacaine-versus-ropivacaine-with-perineural-dexamethasone-or-dexmedetomidine-as-adjuncts-for-adductor-canal-block-combined-with-ipack-block-in-total-knee-arthroplasty-100632144","NCT07509866","Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","A Randomized Trial of Liposomal Bupivacaine, Ropivacaine With Perineural Dexamethasone, and Ropivacaine With Perineural Dexmedetomidine for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients scheduled for elective primary unilateral total knee arthroplasty\n* Age ≥ 18 years and ≤ 80 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body mass index (BMI) ≥ 18 kg\u002Fm² and ≤ 35 kg\u002Fm²\n* Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or contraindication to local anesthetics (bupivacaine, ropivacaine), dexamethasone, dexmedetomidine, or opioids\n* Infection at the injection site\n* Coagulopathy or current use of anticoagulants\n* Severe cardiovascular disease (New York Heart Association \\[NYHA\\] functional class III or IV, or recent myocardial infarction within 6 months)\n* Severe hepatic impairment (Child-Pugh class C) or renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Uncontrolled hypertension (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg despite medical therapy)\n* Uncontrolled diabetes mellitus (HbA1c \\> 8.5%)\n* Bilateral TKA or revision TKA\n* Chronic opioid use (daily opioid consumption for \\> 3 months prior to surgery)\n* Participation in another interventional clinical trial within 30 days prior to enrollment\n* Inability to communicate with study personnel or complete pain assessments (e.g., language barrier, cognitive impairment)","80 Years",{"count":20,"type":21},[137],"Effective postoperative pain management remains a cornerstone of enhanced recovery protocols following total knee arthroplasty (TKA). Inadequate analgesia not only compromises patient satisfaction but also impedes early mobilization and rehabilitation, thereby increasing the risk of perioperative complications. Current multimodal analgesic strategies frequently incorporate regional techniques, with the adductor canal block (ACB) and infiltration between the popliteal artery and capsule of the knee (IPACK) block emerging as established modalities that provide motor-sparing analgesia.\n\nDespite their widespread adoption, the optimal local anesthetic regimen for these blocks remains undefined. While liposomal bupivacaine has garnered interest for its extended duration of action, its clinical efficacy relative to conventional local anesthetics combined with perineural adjuncts remains a subject of ongoing debate. Specifically, perineural dexamethasone and dexmedetomidine have each demonstrated the capacity to prolong the analgesic duration of ropivacaine; however, direct comparative data among these three distinct strategies-liposomal bupivacaine alone versus ropivacaine supplemented with either adjunct-are notably limited.\n\nGiven the absence of head-to-head randomized trials evaluating these three clinically viable techniques, the optimal approach to maximize analgesic duration while minimizing opioid-related adverse effects remains unclear. This study therefore aims to compare the analgesic efficacy and safety profiles of liposomal bupivacaine, ropivacaine with perineural dexamethasone, and ropivacaine with perineural dexmedetomidine when administered via ACB and IPACK blocks in patients undergoing TKA.",[164,165,166,28],"Total Knee Anthroplasty","Nerve Block","Ropivacaine",[168,169,170,35,171,172,36,173,174],"total knee arthroplasty","adductor canal block","IPACK block","ropivacaine","perineural adjuncts","dexmedetomidine","multimodal analgesia","2026-04-09",{"date":177,"type":43},"2026-04-14",{"date":175,"type":43},{"date":180,"type":21},"2026-12-30",{"name":182,"class":50},"Huazhong University of Science and Technology",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":51},"100628178","the-efficacy-and-safety-of-liposomal-bupivacaine-in-relieving-postoperative-pain-after-laparoscopic-surgery-100628178","NCT07458256","The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery","The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Laparoscopic Surgery:A Multi-Center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective laparoscopic cholecystectomy, hernia repair, and appendectomy under general anesthesia;\n2. Ages 18 to 64 years old；\n3. American Society of Anesthesiologists (ASA) physical status of I-III；\n4. Glasgow Coma Scale (GCS) score of 15；\n5. Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause.\n2. Patients with heart conduction block (sinus block or atrioventricular block).\n3. Patients with unstable coronary artery disease.\n4. Patients with gastric ulcer or gastric bleeding.\n5. Patients with diabetes and are being treated with insulin.\n6. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.\n7. Patients with abnormal liver function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.\n8. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) or receiving dialysis treatment within 28 days before surgery.\n9. Patients with a history of diagnosed mental illness or currently taking psychotropic medication.\n10. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.\n11. Pregnancy or breastfeeding.\n12. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35).\n13. Participation in another interventional trial that interferes with the intervention or outcome of this trial.\n14. Patients with a history of allergy to local anaesthetics or one of the study drugs.","64 Years",{"count":192,"type":21},190,[137],"Compared with traditional laparotomy, laparoscopic surgery offers advantages including minimal invasiveness, accelerated patient recovery, and reduced hospital stay. Although postoperative incision pain is generally less severe than that following laparotomy, it remains a notable clinical issue that impedes patient recovery. The majority of patients report incisional discomfort, with approximately 30% to 50% requiring oral analgesics to alleviate pain symptoms. Within the first two days after laparoscopic procedures, most patients experience varying degrees of incisional pain, with peak intensity typically occurring within hours after surgery and gradually subsiding over two to three days. Studies indicate that local infiltration anesthesia at the surgical site significantly ameliorates postoperative incision pain, enhances analgesic efficacy, and shortens recovery time in patients undergoing laparoscopic surgery.Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours. Some researchers have reported the analgesic effects of LB VS traditional local anesthetics infiltration, but the current research results are highly heterogeneous. More prospective studies are needed to evaluate whether LB infiltration is superior to the traditional local anesthetics for the management of postoperative pain. The investigators designed this study to compare the analgesic effect of using LB plus bupivacaine for local infiltration with bupivacaine along for patients after laparoscopic surgery.",[196,28,197],"Laparoscopic Surgery","Local Infiltration","2026-03-14",{"date":200,"type":43},"2026-03-17",{"date":202,"type":43},"2026-03-10",{"date":204,"type":21},"2027-06-30",{"name":206,"class":50},"Beijing Tiantan Hospital",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":190,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":224,"locationsCount":51},"100628181","the-efficacy-and-safety-of-liposomal-bupivacaine-for-transversus-abdominis-plane-block-in-relieving-postoperative-pain-after-laparoscopic-surgery-in-gynecologic-oncology-100628181","NCT07458295","The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology","The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Transversus Abdominis Plane Block for Postoperative Pain in Patients Undergoing Laparoscopic Surgery in Gynecologic Oncology:A Multi-Center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective Laparoscopic Surgery in Gynecologic Oncology under general anesthesia;\n2. Ages 18 to 64 years old；\n3. American Society of Anesthesiologists (ASA) physical status of I-III；\n4. Glasgow Coma Scale (GCS) score of 15；\n5. Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause.\n2. Patients with heart conduction block (sinus block or atrioventricular block).\n3. Patients with unstable coronary artery disease.\n4. Patients with gastric ulcer or gastric bleeding.\n5. Patients with diabetes and are being treated with insulin.\n6. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.\n7. Patients with abnormal liver function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.\n8. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) or receiving dialysis treatment within 28 days before surgery.\n9. Patients with a history of diagnosed mental illness or currently taking psychotropic medication.\n10. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.\n11. Pregnancy or breastfeeding.\n12. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35).\n13. Participation in another interventional trial that interferes with the intervention or outcome of this trial.\n14. Patients with a history of allergy to local anaesthetics or one of the study drugs.",{"count":215,"type":21},110,[137],"Laparoscopic surgery, characterized by minimal invasiveness, rapid recovery, and shorter hospital stays, has been widely adopted in Gynecologic Oncology. However, the elevation and stretching of the diaphragm following pneumoperitoneum, combined with increased intra-abdominal pressure compressing visceral organs and causing ischemia-hypoxia, can trigger systemic inflammatory responses and lead to postoperLaparoscopic surgery, characterized by minimal invasiveness, rapid recovery, and shorter hospital stays, has been widely adopted in gynecological procedures. However, the elevation and stretching of the diaphragm following pneumoperitoneum, combined with increased intra-abdominal pressure compressing visceral organs and causing ischemia-hypoxia, can trigger systemic inflammatory responses and lead to postoperative pain. Inadequate or delayed pain management may prolong hospitalization, and some patients may develop chronic pain, resulting in altered behavioral patterns. As one of the analgesic strategies after abdominal surgery, transversus abdominis plane block (TAPB) not only reduces opioid consumption and the incidence of complications but also avoids adverse effects associated with epidural analgesia. Nevertheless, the analgesic duration provided by a single-injection TAPB is limited, while continuous TAPB faces constraints in clinical application due to challenges such as catheter fixation.Inadequate or delayed pain management may prolong hospitalization, and some patients may develop chronic pain, resulting in altered behavioral patterns. As one of the analgesic strategies after abdominal surgery, TAPB not only reduces opioid consumption and the incidence of complications but also avoids adverse effects associated with epidural analgesia. Nevertheless, the analgesic duration provided by a single-injection TAPB is limited, while continuous TAPB faces constraints in clinical application due to challenges such as catheter fixation. Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours.However, its efficacy and safety in laparoscopic surgery not yet been fully validated. Based on this premise, the present study aims to evaluate and compare the clinical outcomes of Ultrasound-guided TAPB utilizing liposomal bupivacaine plus bupivacaine for postoperative pain management in patients undergoing Laparoscopic Surgery in Gynecologic Oncology.",[196,219,28,220],"Gynecologic Oncology Patient","Transversus Abdominis Plane Block",{"date":200,"type":43},{"date":202,"type":43},{"date":204,"type":21},{"name":206,"class":50},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":190,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":238,"leadSponsor":239,"locationsCount":51},"100628180","the-efficacy-and-safety-of-liposomal-bupivacaine-for-transversus-abdominis-plane-block-in-relieving-postoperative-pain-after-laparoscopic-surgery-100628180","NCT07458282","The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery","The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Transversus Abdominis Plane Block for Postoperative Pain in Patients Undergoing Laparoscopic Surgery:A Multi-Center Randomized Controlled Trial",{"count":232,"type":21},318,[137],"Laparoscopic surgery has become the preferred approach for abdominal surgical interventions due to its advantages of minimal invasiveness, rapid recovery, and reduced complication rates. Despite its minimally invasive nature, postoperative pain persists and adversely affects patient recovery. In the absence of effective pain management, acute pain may progress to chronic pain. Although opioids provide reliable analgesic effects, their associated adverse reactions limit their application following minimally invasive procedures. Regional analgesia serves as the cornerstone of multimodal analgesia, and ultrasound-guided nerve block techniques have become increasingly refined. Ultrasound-guided transversus abdominis plane block(TAPB) generally fulfills intraoperative and postoperative analgesic requirements for laparoscopic surgeries by inhibiting the transmission of nociceptive stimuli in the targeted region, thereby aiding in the prevention of central sensitization. Conventional TAPB utilize local anesthetics, which demonstrate excellent efficacy in alleviating incisional pain. However, the short duration of analgesia provided by conventional local anesthetics significantly compromises their clinical utility.Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours.However, its efficacy and safety in laparoscopic surgery not yet been fully validated. Based on this premise, the present study aims to evaluate and compare the clinical outcomes of Ultrasound-guided TAPB utilizing liposomal bupivacaine plus bupivacaine for postoperative pain management in patients undergoing laparoscopic surgery.",[196,28,220],{"date":200,"type":43},{"date":202,"type":43},{"date":204,"type":21},{"name":206,"class":50},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":190,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":51},"100626213","the-efficacy-and-safety-of-liposomal-bupivacaine-in-relieving-postoperative-pain-after-video-assisted-thoracoscopic-surgery-100626213","NCT07432711","The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery","The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective video-assisted thoracoscopic lobectomy or wedge resection under general anesthesia;\n2. Ages 18 to 64 years old；\n3. American Society of Anesthesiologists (ASA) physical status of I-III；\n4. Glasgow Coma Scale (GCS) score of 15；\n5. Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause.\n2. Patients with heart conduction block (sinus block or atrioventricular block).\n3. Patients with unstable coronary artery disease.\n4. Patients with gastric ulcer or gastric bleeding.\n5. Patients with diabetes and are being treated with insulin.\n6. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.\n7. Patients with abnormal liver function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.\n8. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) or receiving dialysis treatment within 28 days before surgery.\n9. Patients with a history of diagnosed mental illness or currently taking psychotropic medication.\n10. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.\n11. Pregnancy or breastfeeding.\n12. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35).\n13. Participation in another interventional trial that interferes with the intervention or outcome of this trial.\n14. Patients with a history of allergy to local anaesthetics or one of the study drugs.",{"count":248,"type":21},100,[137],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy. It is reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process.If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Local infiltration anesthesia at the incision site is one of the simplest, safest, and most effective methods for preventing postoperative incision pain. Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours. Some researchers have reported the analgesic effects of LB VS traditional local anesthetics infiltration, but the current research results are highly heterogeneous. More prospective studies are needed to evaluate whether LB infiltration is superior to the traditional local anesthetics for the management of postoperative pain. The investigators designed this study to compare the analgesic effect of using LB plus bupivacaine for local infiltration with bupivacaine along for patients after VATS.",[252,118,28,253],"Video-assisted Thoracoscopic Surgery (VATS)","Local Injection","2026-03-05",{"date":256,"type":43},"2026-03-06",{"date":258,"type":43},"2026-03-02",{"date":204,"type":21},{"name":206,"class":50},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":190,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":276,"leadSponsor":277,"locationsCount":51},"100626920","the-efficacy-and-safety-of-liposomal-bupivacaine-for-rhomboid-intercostal-nerve-block-in-relieving-postoperative-pain-after-video-assisted-thoracoscopic-surgery-100626920","NCT07441902","The Efficacy and Safety of Liposomal Bupivacaine for Rhomboid Intercostal Nerve Block in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery","Ultrasound-Guided Liposomal Bupivacaine Plus Bupivacaine Rhomboid Intercostal Block for Postoperative Pain Relief in Patients Undergoing Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled for elective video-assisted thoracoscopic lobectomy or wedge resection under general anesthesia;\n* Ages 18 to 64 years old；\n* American Society of Anesthesiologists (ASA) physical status of I-III；\n* Glasgow Coma Scale (GCS) score of 15；\n* Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.\n\nExclusion Criteria:\n\n* History of chronic pain syndrome of any cause.\n* Patients with heart conduction block (sinus block or atrioventricular block).\n* Patients with unstable coronary artery disease.\n* Patients with gastric ulcer or gastric bleeding.\n* Patients with diabetes and are being treated with insulin.\n* Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.\n* Patients with abnormal liver function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.\n* Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) or receiving dialysis treatment within 28 days before surgery.\n* Patients with a history of diagnosed mental illness or currently taking psychotropic medication.\n* Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.\n* Pregnancy or breastfeeding.\n* Extreme body mass index (BMI) (\\\u003C 15 or \\> 35).\n* Participation in another interventional trial that interferes with the intervention or outcome of this trial.\n* Patients with a history of allergy to local anaesthetics or one of the study drugs.",{"count":269,"type":21},134,[137],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy. It is reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process.If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge.In recent years, multimodal postoperative analgesia protocols have been increasingly adopted in clinical practice. The Rhomboid intercostal block (RIB), as a novel regional anesthesia technique within the multimodal analgesia framework, has been widely utilized in various thoracic surgical procedures. Liposomal bupivacaine, an innovative long-acting sustained-release amide local anesthetic, provides prolonged analgesia for up to 72 hours. However, its efficacy and safety in video-assisted thoracoscopic surgery (VATS) have not yet been fully validated. Based on this premise, the present study aims to evaluate and compare the clinical outcomes of ultrasound-guided Rhomboid intercostal block (RIB) utilizing liposomal bupivacaine combined with conventional bupivacaine for postoperative pain management in patients undergoing VATS.",[252,118,28,273],"Rhomboid Intercostal Block",{"date":256,"type":43},{"date":258,"type":43},{"date":204,"type":21},{"name":206,"class":50},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":288,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":51},"100613852","liposomal-bupivacaine-versus-ropivacaine-for-preperitoneal-infiltration-analgesia-in-upper-abdominal-laparotomy-100613852","NCT07271979","Liposomal Bupivacaine Versus Ropivacaine for Preperitoneal Infiltration Analgesia in Upper Abdominal Laparotomy","Liposomal Bupivacaine Versus Ropivacaine for Preperitoneal Infiltration Analgesia in Upper Abdominal Laparotomy: A Randomized Double-Blind Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 75 years; for those \\>70 years old, a Karnofsky Performance Status (KPS) score ≥80 is required.\n2. Scheduled for elective upper abdominal laparotomy.\n3. Surgical approach involving either a subcostal or midline incision.\n4. Incision length between 15 and 30 cm.\n5. American Society of Anesthesiologists (ASA) physical status classification of I to III.\n\nExclusion Criteria:\n\n1. ASA Physical Status Class greater than III.\n2. Pre-existing chronic pain with long-term opioid use (for \\>1 year).\n3. Significant hepatic or renal impairment, or underweight status, defined as:\n\n   Estimated glomerular filtration rate (eGFR) of \\\u003C40 mL\u002Fmin\u002F1.73m²; Child-Pugh Class C; Body Mass Index (BMI) \\\u003C18.5 kg\u002Fm².\n4. Known allergy or hypersensitivity to the investigational drug or any of its excipients.\n5. Pregnancy or lactation","75 Years",{"count":287,"type":21},146,[137],"Upper abdominal open surgery is associated with significant trauma, and postoperative pain management poses considerable challenges. The inflammatory response triggered by peritoneal incision and the transmission of visceral pain via the vagus nerve are key components of \"surgical stress\" and pain. A potential intervention strategy involves the local administration of anesthetic agents to suppress peritoneal overreaction and block the cascade of pro-inflammatory cytokines in related nerves. Liposomal bupivacaine, as a long-acting local anesthetic, may provide more prolonged postoperative analgesia compared to ropivacaine. Therefore, this trial aims to prospectively compare the analgesic efficacy and anti-inflammatory effects of the two drugs when administered as pre-closure preperitoneal infiltration. Secondary endpoints include opioid consumption, complication rates, and postoperative recovery indicators, to comprehensively evaluate their clinical value.",[28,291,292],"Preperitoneal Infiltration","Analgesia","2026-02-24",{"date":295,"type":43},"2026-02-27",{"date":297,"type":43},"2026-01-04",{"date":299,"type":21},"2026-06",{"name":301,"class":50},"Qilu Hospital of Shandong University",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":308,"minAge":17,"maxAge":159,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":314,"conditions":315,"keywords":320,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":51},"100615174","phase-1-effect-of-liposome-bupivacaine-serratus-plane-block-on-postoperative-hyperalgesia-and-chronic-post-surgical-pain-in-patients-undergoing-radical-mastectomy-100615174","NCT07289178","Effect of Liposome Bupivacaine Serratus Plane Block on Postoperative Hyperalgesia and Chronic Post-surgical Pain in Patients Undergoing Radical Mastectomy","Inclusion Criteria:\n\nSelect patients scheduled for elective radical mastectomy for breast cancer under general anesthesia, ASA grade I-IV, aged 18-80 years.\n\nExclusion Criteria:\n\nAllergy to the anesthetics used, infection at the puncture site, history of chronic pain and current use of opioid analgesics, history of chest surgery or trauma, drug or alcohol dependence, neurological or psychiatric disorders, severe hepatic or renal insufficiency, pregnancy, body mass index (BMI) greater than 30 kg\u002Fm².","FEMALE",{"count":310,"type":21},120,[312,313],"PHASE1","PHASE2","Radical mastectomy is currently the mainstream surgical treatment for breast cancer. Patients often experience significant postoperative pain, and some may develop chronic pain. General anesthesia is commonly used, with remifentanil being the most frequently used intraoperative analgesic. However, prolonged high-dose use of remifentanil can induce opioid-induced hyperalgesia (OIH). Previous studies have shown that serratus anterior plane block can reduce acute postoperative pain after radical mastectomy, but it remains unclear whether it can reduce postoperative pain sensitization and the incidence of chronic pain. Liposomal bupivacaine is a new long-acting local anesthetic with an effect lasting up to 72 hours. This study aims to investigate the effect of liposomal bupivacaine serratus anterior plane block on postoperative pain sensitization and chronic pain in patients undergoing radical mastectomy, providing a reference for clinical treatment. The study includes 120 participants. A tactile measurement kit is used to measure the mechanical pain threshold around the surgical incision preoperatively and at 24 and 48 hours postoperatively, as well as postoperative persistent pain scores at 7 days, 1 month, 3 months, and 6 months. The data will then be analyzed to draw conclusions.",[316,317,318,28,319],"Serratus Plane Block","Postoperative Hyperalgesia","Chronic Post-surgical Pain","Radical Mastectomy Surgery",[321,322,323,28,324],"serratus plane block","postoperative hyperalgesia","chronic post-surgical pain","Radical mastectomy surgery","2025-12-04",{"date":327,"type":43},"2025-12-17",{"date":329,"type":21},"2026-01-01",{"date":180,"type":21},{"name":332,"class":50},"First Affiliated Hospital of Kunming Medical University",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":348,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":51},"100572972","phase-3-analgesic-efficacy-of-different-liposomal-bupivacaine-doses-in-the-adductor-canal-block-for-total-knee-arthroplasty-100572972","NCT06740214","Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty","Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty: a Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA I-III\n* Age 18-80 years old\n* Scheduled for elective primary unilateral total knee arthroplasty (TKA) with robotic surgery\n* Able to speak and understand Cantonese or Mandarin or English\n* Able to provide informed oral and written consent\n\nExclusion Criteria:\n\n* Revision TKA\n* Single-stage bilateral TKA\n* Complex primary TKA requiring use of stem\u002Faugment\u002Fconstrained liner\n* Surgeries with significant intraoperative complications which may alter rehabilitation protocol eg collateral ligament injury, fracture requiring fixation\n* Known allergy to opioids, local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS) including COX-2 inhibitors\n* History of chronic pain other than chronic knee pain\n* History of immunosuppression\n* Chronic use of glucocorticoids\n* Chronic opioid use (morphine, fentanyl, hydromorphone, ketobemidone, methadone, nicomorphine, oxycodone, or meperidine)\n* History of congestive heart failure (NYHA 2)\n* Alcohol or drug abuse\n* Impaired renal function (defined as effective glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m2\n* Impaired liver function (defined as plasma bilirubin over 34mol\u002FL; international normalized ratio \\[INR\\] \\>= 1.7, alanine aminotransferase \\[ALT\\] over 100U\u002FL, aspartate aminotransferase \\[AST\\] over 100U\u002FL)\n* Coagulopathy (platelet count \\\u003C100,000\u002Fml and\u002For INR \\>= 1.5) or the use of anticoagulants (not including aspirin) that precludes the use of adductor canal blocks\n* Pre-existing neurological or muscular disorders\n* Psychiatric illness\n* Impaired mental state\n* Pregnancy\n* Local infection\n* On immunosuppressants\n* High body mass index (BMI) (\\>=40)\n* Patient refusal for regional nerve blocks or to conduct clinical trial",{"count":341,"type":21},177,[24],"Total knee arthroplasty is a commonly performed orthopaedic surgery for the treatment of end-stage osteoarthritis when conservative management becomes ineffective. TKA is associated with significant acute postoperative pain and many patients experience severe postoperative pain despite the use of multimodal analgesia. Poor acute postoperative pain control impacts rehabilitation, prolongs recovery and increases opioid consumption and chronic post-surgical pain.\n\nLiposomal bupivacaine (Exparel, Pacira Pharmaceuticals Inc, Parsippany, New Jersey, USA) is a multivesicular formulation of bupivacaine that prolongs drug release and can extend the duration of analgesia. The adductor canal block (ACB) has been shown to reduce pain intensity and opioid consumption after total knee arthroplasty. The use of liposomal bupivacaine in the adductor canal block has recently been FDA-approved. However, the results of its efficacy from existing clinical trials have been mixed. In addition, the doses in the clinical trials have been different, and the optimal dose for perineural application of liposomal bupivacaine is unclear, including for the adductor canal block.\n\nIn this project, the investigators propose to conduct a randomized controlled trial to investigate the effect of different doses of liposomal bupivacaine in the adductor canal block on acute postoperative pain intensity and opioid consumption after robotic assisted total knee arthroplasty. The investigators will also assess secondary outcomes including knee functional scores, chronic pain and quality of recovery.",[27,345,346,28,347],"Analgesic Effect","Total Knee Arthroplasty","Dose Response Relationship, Drug",[169,349,35,350,168],"local infiltration analgesia","opioid consumption","2025-11-18",{"date":353,"type":43},"2025-11-24",{"date":355,"type":43},"2025-09-04",{"date":357,"type":21},"2028-06-30",{"name":49,"class":50},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":4},"100611800","early-phase-1-effect-of-local-infiltration-of-liposomal-bupivacaine-on-postoperative-analgesia-in-patients-with-craniotomy-microvascular-decompression-100611800","NCT07245290","Effect of Local Infiltration of Liposomal Bupivacaine on Postoperative Analgesia in Patients With Craniotomy Microvascular Decompression","Effect of Local Infiltration of Liposomal Bupivacaine on Postoperative Analgesia in Patients With Craniotomy Microvascular Decompression: a Randomized Controlled Study","Inclusion Criteria:\n\n* (1) Age ≥ 18 years old;\n* (2) ASA classification ≤ III grade, patients scheduled to undergo craniotomy and microvascular decompression surgery.\n\nExclusion Criteria:\n\n* (1) Trauma or emergency patients;\n* (2) Patients with cardiac conduction block (sinus node conduction block or atrioventricular conduction block);\n* (3) Patients with coagulation dysfunction;\n* (4) Patients who have abused alcohol or had severe dependence on anesthetic drugs within the past 2 months;\n* (5) Patients with uncontrolled anxiety disorder, schizophrenia or other mental illnesses;\n* (6) Patients with a history of allergy to local anesthetics or non-steroidal drugs.",{"count":248,"type":21},[368],"EARLY_PHASE1","Background: Approximately 60-84% of patients undergoing craniotomy experience moderate to severe pain within 48 hours postoperatively, with posterior fossa craniotomy patients experiencing more severe pain. Microvascular decompression (MVD) is a type of posterior fossa surgery. Traditional analgesic regimens rely on intravenous opioids, but these have significant side effects. Currently, local infiltration at the incision site is a simple and effective analgesic method in multimodal analgesia protocols after craniotomy. Liposomal bupivacaine (Exparel®) is a new type of sustained-release local anesthetic. Its liposome encapsulation technology can extend the drug release time to 72 hours, covering the entire time window of postoperative acute pain and helping patients better control pain.\n\nObjective: This study aims to explore the efficacy of local infiltration of liposomal bupivacaine at the scalp incision in acute pain after microvascular decompression in neurosurgery and provide evidence for clinical practice.\n\nMethods: This study is a single-center, prospective, randomized controlled trial. A total of 100 patients scheduled for elective craniotomy for microvascular decompression will be enrolled. They will be randomly assigned to the liposomal bupivacaine incision infiltration group (LB group) or the conventional treatment control group (C group). After induction of general anesthesia, in the LB group, after preoperative disinfection and draping, the surgeon will perform layer-by-layer infiltration of the incision (subcutaneous → muscle → periosteum) before skin incision. In the C group, the routine procedure of direct disinfection and draping followed by skin incision will be performed. Both groups will receive standardized multimodal analgesia after returning to the ward. The primary outcome measure is the area under the curve of the numerical rating scale (NRS) for rest pain from 0 to 72 hours postoperatively (AUC NRS-R0-72). Secondary outcome measures include the time to first analgesic request within 72 hours postoperatively; rescue analgesia within 72 hours postoperatively (opioid analgesics converted to morphine milligram equivalents); NRS scores at 6, 12, 24, 48, and 72 hours postoperatively; hemodynamic data: heart rate and blood pressure at skin incision, 1 hour after skin incision, 2 hours after skin incision, at the end of surgery, and 1 hour postoperatively; QoR-15 score at 72 hours postoperatively; and length of hospital stay and hospitalization costs.",[28,371],"Microvascular Decompression",[28,373,374],"Microvascular decompression","scalp infiltration","2025-11-17",{"date":353,"type":43},{"date":378,"type":21},"2025-11",{"date":380,"type":21},"2026-12",{"name":126,"class":50}]